NASDAQ:CDIO

Cardio Diagnostics Q2 2026 Earnings Results & Report

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics reported Q2 2026 earnings on August 7, 2026. The company reported EPS of -$0.51, while revenue was $10 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Cardio Diagnostics EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Cardio Diagnostics Revenue Results

Actual Revenue
$10 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardio Diagnostics Q2 2026 Earnings FAQ

Cardio Diagnostics (NASDAQ:CDIO) reported earnings of -$0.51 per share for Q2 2026. The report was announced on Friday, August 7, 2026.

Cardio Diagnostics reported revenue of $10 thousand for Q2 2026.

Cardio Diagnostics Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease.

The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

Founded in 2017 and based in Chicago, Illinois, Cardio Diagnostics was co-founded by Meesha Dogan, who serves as its chief executive officer. The company focuses primarily on making its testing services available in the United States.

View Cardio Diagnostics Profile